Phase 1, Open-Label, Dose Escalation Study of I-131-CLR1404 in Patients With Relapsed or Refractory Multiple Myeloma
Phase of Trial: Phase I
Latest Information Update: 16 Sep 2019
Price : $35 *
At a glance
- Drugs CLR 1404 I-131 (Primary) ; Dexamethasone
- Indications Multiple myeloma
- Focus Adverse reactions; Proof of concept
- Sponsors Cellectar Biosciences
- 16 Sep 2019 According to a Cellectar Biosciences media release, the trial have progressed to a higher 40 mCi/m2 fractionated dose Cohort 7 with a data expected in Q4 2019.
- 16 Sep 2019 According to a Cellectar Biosciences media release, data from cohort 6 of this study were presented at the at the 17th International Myeloma Workshop being held in Boston, MA from September 12-15, 2019.
- 16 Sep 2019 Results presented in the Cellectar Biosciences media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History